News und Analysen

Following the market's gloomy 2022, this year has been a breath of fresh air with the S&P 500 rising 14% so far in 2023. Some biotech stocks have soared even higher thanks to strong products. Cystic

Novo Nordisk's (NYSE: NVO) molecule semaglutide is the active ingredient in its smash-hit therapies for weight loss and diabetes, which you've probably heard of under the trade names Wegovy and

News from the Food and Drug Administration (FDA) can often make or break a stock. This month, it broke Sage Therapeutics (NASDAQ: SAGE).

Although the company obtained approval for its depression

Growth stocks have hit a rough patch lately. The Nasdaq Composite, a benchmark for many growth-oriented companies, has declined by about 5% since the beginning of August, and many individual growth

If Wall Street is having a back-to-school sale, Cathie Wood is shopping. The widely followed growth investor who leads Ark Invest did a fair amount of buying on Tuesday. She publishes her daily

More than three years after deeming COVID-19 a global health emergency, the World Health Organization ended the pandemic's special status in May.

This was certainly welcome news for numerous

Unprofitable clinical-stage biotechs have lost their appeal in the past year, given the challenging economic and market conditions we still haven't entirely left behind. That's why companies such as

By some estimates, the market for nonalcoholic steatohepatitis (NASH) medicines will be worth a startling $108 billion by 2030, even though no drugs are yet on the market for it. That makes it a

Tuesday was a fine day to be a Medtronic (NYSE: MDT) investor. The company's performance in its inaugural quarter of fiscal 2024 was better than expected, and the market rewarded Medtronic shares

Image source: The Motley Fool.

Medtronic (NYSE: MDT)Q1 2024 Earnings CallAug 22, 2023, 8:00 a.m. ET

Ryan Weispfenning

Continue reading

Source Fool.com

Investors in Novavax (NASDAQ: NVAX) haven't had much to celebrate recently, but the stock is rocketing higher on Tuesday. As of 11:30 a.m. ET, Novavax shares were up more than 17%, despite the

The healthcare sector is a hotbed of innovation, and those companies that genuinely break new ground are often handsomely rewarded, along with their shareholders. Investors looking to earn outsized

The healthcare sector is a hotbed of innovation, and those companies that genuinely break new ground are often handsomely rewarded, along with their shareholders. Investors looking to earn outsized

Wall Street analysts are upbeat on California-based biotech Illumina (NASDAQ: ILMN) these days, estimating on average that the stock could climb by up to 27% over the next year. But without some

Wall Street analysts are upbeat on California-based biotech Illumina (NASDAQ: ILMN) these days, estimating on average that the stock could climb by up to 27% over the next year. But without some

Wall Street analysts are upbeat on California-based biotech Illumina (NASDAQ: ILMN) these days, estimating on average that the stock could climb by up to 27% over the next year. But without some

Buying individual stocks can be a smart way to build wealth over time. However, the reality of the situation is that it's exceptionally difficult to consistently beat the market averages over time

Buying individual stocks can be a smart way to build wealth over time. However, the reality of the situation is that it's exceptionally difficult to consistently beat the market averages over time

Buying individual stocks can be a smart way to build wealth over time. However, the reality of the situation is that it's exceptionally difficult to consistently beat the market averages over time

Regeneron Pharmaceuticals (NASDAQ: REGN) is a leader in the field of therapeutic proteins, with a history of more than 30 years of innovation and excellence. The biotech has partnered with Bayer to